PHO and OSAKA Related Headlines

Go Back

Mar 3, 2026 04:52AM Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions

Feb 18, 2026 01:40AM Photocure ASA: Results for the fourth quarter of 2025

Dec 8, 2025 02:27AM The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison

Oct 29, 2025 02:21AM Photocure ASA: Results for the third quarter of 2025

Oct 15, 2025 11:21AM Photocure and Intelligent Scopes Corporation partner on development of AI for blue light cystoscopy

Jul 30, 2025 01:09AM Photocure ASA: Results for the second quarter of 2025

PHO and OSAKA Related Press Releases

Go Back

Mar 3, 2026 04:52AM Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions

Feb 18, 2026 01:40AM Photocure ASA: Results for the fourth quarter of 2025

Dec 8, 2025 02:27AM The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison

Oct 29, 2025 02:21AM Photocure ASA: Results for the third quarter of 2025

Oct 15, 2025 11:21AM Photocure and Intelligent Scopes Corporation partner on development of AI for blue light cystoscopy

Jul 30, 2025 01:09AM Photocure ASA: Results for the second quarter of 2025

PHO and OSAKA Related SEC Filings

Go Back